Status:
COMPLETED
Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease
Lead Sponsor:
University of Dundee
Collaborating Sponsors:
NHS Tayside
British Heart Foundation
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
35-85 years
Phase:
PHASE4
Brief Summary
Peripheral arterial disease (PAD) is a common condition that arises due to the build up of atheroma in the arteries supplying blood to the peripheral muscles and other tissues. This imbalance between ...
Detailed Description
The investigators will recruit 50 patients with peripheral arterial disease for a randomised, double-blind, placebo-controlled parallel group study to see if allopurinol prolongs time to leg pain and ...
Eligibility Criteria
Inclusion
- \- stable peripheral arterial disease (demonstrated by having a reproducible pain free walking distance on 2 consecutive treadmill tests, i.e. less than 25% variance with the reason for termination of the treadmill test must be claudication pain only)
Exclusion
- rest pain
- childbearing potential
- heart failure
- any other exercise limiting cardiac disease
- BP \> 180/100 mHg
- eGFR \< 60 ml/min
- liver disease
- malignancy
- already on allopurinol or had an adverse reaction to it
- recent marked change in symptoms or recent (in the last six months) intervention for PAD
- receiving treatment with either 6-mercaptopurine, azathioprine, warfarin, or theophylline
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01147705
Start Date
February 1 2011
End Date
July 1 2012
Last Update
May 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY